Dr. Yellapragada is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2002 Holcombe Blvd
Department Of Hematology Oncology
Houston, TX 77030Phone+1 713-791-1414Fax+1 713-794-7733- Is this information wrong?
Education & Training
Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2005 - 2008
Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 2002 - 2005
Madras Medical CollegeClass of 2000
Certifications & Licensure
TX State Medical License 2007 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting Start of enrollment: 2010 Dec 02
- Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma Start of enrollment: 2010 Aug 01
- Feasibility of a Tele-game-based Exercise (Tele-exergame) Program to Prevent Deconditioning in Hospitalized COVID-19 Patients Start of enrollment: 2021 Jul 05
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Dyspneic and pink.Jack Badawy, Ameer Ahmed, Andrew White, Christian Inchaustegui, Sarvari Yellapragada, Zaven Sargsyan> ;Journal of Hospital Medicine. 2024 Apr 2
- Ibrutinib-associated cutaneous mucormycosis due to anspecies: report of a case and review of the literature.Lynne Chapman, Richard J Hamill, Trung Minh Nguyen, Eva Amenta, Sarvari Yellapragada, Bhuvaneswari Krishnan, Jonathan Lim> ;Therapeutic Advances in Infectious Disease. 2024 Mar 26
- Harnessing physical activity monitoring and digital biomarkers of frailty from pendant based wearables to predict chemotherapy resilience in veterans with cancer.Cay, G., Dehghan Rouzi, M., Uddin Atique, M., Rodriguez, N., Azarian, M., Finco, M., Najafi, B., Sada, Y., Yellapragada, S.> ;Scientific Reports. 2024 Jan 31
- Join now to see all
Abstracts/Posters
- With Equal Access, African Americans with Non-del17p Multiple Myeloma Have Superior Overall Survival, but del17p Still Carries Poor Prognosis across Race: A VA StudySarvari Venkata Yellapragada, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Differential Induction Among Younger Patients Diagnosed with Secondary Acute Myelogenous Leukemia Is Feasible By Cytogenetic/Molecular Risk StratificationSarvari Venkata Yellapragada, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Incidence of Second Primary Malignancies and Association with Treatment in US Veterans with Multiple MyelomaSarvari Venkata Yellapragada, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Predictive Factors for Complete Remission and Survival in AML Patients Failing to Achieve Adequate Bone Marrow Day 14 Blast Eradication2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Vitamin D Deficiency Predicts for Poor Overall Survival in Caucasian but Not African American Patients with Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Reaching the ‘Unreachable’: The Final Frontier in MedicineJanuary 15th, 2021
Hospital Affiliations
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
